Skip to main content
Erschienen in: Tumor Biology 3/2013

01.06.2013 | Research Article

The regulatory mechanism of CCR7 gene expression and its involvement in the metastasis and progression of gastric cancer

verfasst von: Wei-ning Wang, Yuxiang Chen, Yang-de Zhang, Tie-hui Hu

Erschienen in: Tumor Biology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Gastric cancer is the second leading cause of cancer mortality, but the molecular mechanisms underlying its progression and metastasis remain unclear. CCR7 and Dicer 1 protein expression in 80 gastric adenocarcinomas and 40 peritumoral tissues were measured by immunohistochemical staining. The expression of let-7a miRNA in serum, tumor tissues, and peritumoral tissues was measured by real-time PCR. The role of let-7a in CCR7 protein expression, migration, and invasion of gastric cancer cells was tested in vitro. Dicer 1 protein expression was found to be significantly reduced, whereas CCR7 protein expression was significantly increased in gastric adenocarcinomas compared to peritumoral tissues. The let-7a miRNA levels in the serum and tumor tissues of gastric adenocarcinoma patients were significantly lower than in the serum of healthy controls and peritumoral tissues, respectively. Dicer 1 protein positively correlated with let-7a miRNA level, but negatively correlated with CCR7 protein level in gastric adenocarcinoma. Negative Dicer 1 protein and let-7a miRNA expression and positive CCR7 protein expression significantly correlated with lymph node metastasis, depth of invasion, high clinical TNM stage, and larger tumor size. Let-7a transfection significantly inhibited CCR7 protein expression, migration, and invasion of MNK-45 cells in vitro. High expression of CCR7 protein and low expression of Dicer 1 protein and let-7a miRNA are significantly associated with the metastasis and progression of gastric cancer. High CCR7 protein expression may be caused by the loss of Dicer 1 protein expression and reduced let-7a miRNA level in gastric cancer. The serum let-7a level might be a marker for the diagnosis of gastric cancer.
Literatur
1.
Zurück zum Zitat Mashino K, Sadanaga N, Yamaguchi H, Tanaka F, Ohta M, Shibuta K, et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 2002;62:2937–41.PubMed Mashino K, Sadanaga N, Yamaguchi H, Tanaka F, Ohta M, Shibuta K, et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 2002;62:2937–41.PubMed
2.
Zurück zum Zitat Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol. 2000;12:336–41.PubMedCrossRef Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol. 2000;12:336–41.PubMedCrossRef
3.
Zurück zum Zitat Kodama J, Hasengaowa, Seki N, Kusumoto T, Hiramatsu Y. Expression of the CXCR4 and CCR7 chemokine receptors in human endometrial cancer. Eur J Gynaecol Oncol. 2007;28:370–5.PubMed Kodama J, Hasengaowa, Seki N, Kusumoto T, Hiramatsu Y. Expression of the CXCR4 and CCR7 chemokine receptors in human endometrial cancer. Eur J Gynaecol Oncol. 2007;28:370–5.PubMed
4.
Zurück zum Zitat Arigami T, Natsugoe S, Uenosono Y, Yanagita S, Arima H, Hirata M, et al. CCR7 and CXCR4 expression predicts lymph node status including micrometastasis in gastric cancer. Int J Oncol. 2009;35:19–24.PubMedCrossRef Arigami T, Natsugoe S, Uenosono Y, Yanagita S, Arima H, Hirata M, et al. CCR7 and CXCR4 expression predicts lymph node status including micrometastasis in gastric cancer. Int J Oncol. 2009;35:19–24.PubMedCrossRef
5.
Zurück zum Zitat Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gönner U, Wilsberg V, et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 2005;11:1743–50.PubMedCrossRef Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gönner U, Wilsberg V, et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 2005;11:1743–50.PubMedCrossRef
6.
Zurück zum Zitat Walser TC, Fulton AM. The role of chemokines in the biology and therapy of breast cancer. Breast Dis. 2004;20:137–43.PubMed Walser TC, Fulton AM. The role of chemokines in the biology and therapy of breast cancer. Breast Dis. 2004;20:137–43.PubMed
7.
Zurück zum Zitat Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20:515–24.PubMedCrossRef Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20:515–24.PubMedCrossRef
8.
Zurück zum Zitat Bagga S, Pasquinelli AE. Identification and analysis of microRNAs. Genet Eng (N Y). 2006;27:1–20.CrossRef Bagga S, Pasquinelli AE. Identification and analysis of microRNAs. Genet Eng (N Y). 2006;27:1–20.CrossRef
9.
Zurück zum Zitat Xiong J, Du Q, Liang Z. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene. 2010;29:4980–8.PubMedCrossRef Xiong J, Du Q, Liang Z. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene. 2010;29:4980–8.PubMedCrossRef
10.
Zurück zum Zitat Song JH, Meltzer SJ. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology. 2012;143:35–47.PubMedCrossRef Song JH, Meltzer SJ. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology. 2012;143:35–47.PubMedCrossRef
11.
Zurück zum Zitat Song B, Ju J. Impact of miRNAs in gastrointestinal cancer diagnosis and prognosis. Expert Rev Mol Med. 2010;12:e33.PubMedCrossRef Song B, Ju J. Impact of miRNAs in gastrointestinal cancer diagnosis and prognosis. Expert Rev Mol Med. 2010;12:e33.PubMedCrossRef
12.
Zurück zum Zitat Kim SJ, Shin JY, Lee KD, Bae YK, Sung KW, Nam SJ, et al. MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res. 2012;14:R14.PubMedCrossRef Kim SJ, Shin JY, Lee KD, Bae YK, Sung KW, Nam SJ, et al. MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res. 2012;14:R14.PubMedCrossRef
13.
Zurück zum Zitat Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001;409:363–6.PubMedCrossRef Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001;409:363–6.PubMedCrossRef
14.
Zurück zum Zitat Macrae IJ, Zhou K, Li F, Repic A, Brooks AN, Cande WZ, et al. Structural basis for double-stranded RNA processing by Dicer. Science. 2006;311:195–8.PubMedCrossRef Macrae IJ, Zhou K, Li F, Repic A, Brooks AN, Cande WZ, et al. Structural basis for double-stranded RNA processing by Dicer. Science. 2006;311:195–8.PubMedCrossRef
15.
Zurück zum Zitat Dedes KJ, Natrajan R, Lambros MB, Geyer FC, Lopez-Garcia MA, Savage K, et al. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer. 2011;47:138–50.PubMedCrossRef Dedes KJ, Natrajan R, Lambros MB, Geyer FC, Lopez-Garcia MA, Savage K, et al. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer. 2011;47:138–50.PubMedCrossRef
16.
Zurück zum Zitat Yamada T, Sato K, Komachi M, Malchinkhuu E, Tobo M, Kimura T, et al. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem. 2004;279:6595–605.PubMedCrossRef Yamada T, Sato K, Komachi M, Malchinkhuu E, Tobo M, Kimura T, et al. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem. 2004;279:6595–605.PubMedCrossRef
17.
Zurück zum Zitat Komachi M, Tomura H, Malchinkhuu E, Tobo M, Mogi C, Yamada T, et al. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. Carcinogenesis. 2009;30:457–65.PubMedCrossRef Komachi M, Tomura H, Malchinkhuu E, Tobo M, Mogi C, Yamada T, et al. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. Carcinogenesis. 2009;30:457–65.PubMedCrossRef
18.
Zurück zum Zitat Yang Q, Jie Z, Cao H, Greenlee AR, Yang C, Zou F, et al. Low-level expression of let-7a in gastric cancer and its involvement in tumorigenesis by targeting RAB40C. Carcinogenesis. 2011;32:713–22.PubMedCrossRef Yang Q, Jie Z, Cao H, Greenlee AR, Yang C, Zou F, et al. Low-level expression of let-7a in gastric cancer and its involvement in tumorigenesis by targeting RAB40C. Carcinogenesis. 2011;32:713–22.PubMedCrossRef
19.
Zurück zum Zitat Ishigami S, Natsugoe S, Nakajo A, Tokuda K, Uenosono Y, Arigami T, et al. Prognostic value of CCR7 expression in gastric cancer. Hepatogastroenterology. 2007;54:1025–8.PubMed Ishigami S, Natsugoe S, Nakajo A, Tokuda K, Uenosono Y, Arigami T, et al. Prognostic value of CCR7 expression in gastric cancer. Hepatogastroenterology. 2007;54:1025–8.PubMed
20.
Zurück zum Zitat Li X, Zhang Y, Zhang Y, Ding J, Wu K, Fan D. Survival prediction of gastric cancer by a seven-microRNA signature. Gut. 2010;59:579–85.PubMedCrossRef Li X, Zhang Y, Zhang Y, Ding J, Wu K, Fan D. Survival prediction of gastric cancer by a seven-microRNA signature. Gut. 2010;59:579–85.PubMedCrossRef
21.
Zurück zum Zitat Zhu Y, Zhong Z, Liu Z. Lentiviral vector-mediated upregulation of let-7a inhibits gastric carcinoma cell growth in vitro and in vivo. Scand J Gastroenterol. 2011;46:53–9.PubMedCrossRef Zhu Y, Zhong Z, Liu Z. Lentiviral vector-mediated upregulation of let-7a inhibits gastric carcinoma cell growth in vitro and in vivo. Scand J Gastroenterol. 2011;46:53–9.PubMedCrossRef
22.
Zurück zum Zitat Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007;39:673–7.PubMedCrossRef Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007;39:673–7.PubMedCrossRef
23.
Zurück zum Zitat Kumar MS, Pester RE, Chen CY, Lane K, Chin C, Lu J, et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 2009;23:2700–27404.PubMedCrossRef Kumar MS, Pester RE, Chen CY, Lane K, Chin C, Lu J, et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 2009;23:2700–27404.PubMedCrossRef
Metadaten
Titel
The regulatory mechanism of CCR7 gene expression and its involvement in the metastasis and progression of gastric cancer
verfasst von
Wei-ning Wang
Yuxiang Chen
Yang-de Zhang
Tie-hui Hu
Publikationsdatum
01.06.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 3/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0728-9

Weitere Artikel der Ausgabe 3/2013

Tumor Biology 3/2013 Zur Ausgabe

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.